Boston Scientific Corporation (NYSE: BSX), a Marlborough, MA-based medical solutions provider, announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.
The purchase price of $71 cash per share represents an equity value of $3.7 billion and an enterprise value of $3.3 billion. The transaction is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and accretive thereafter. On a GAAP basis, the transaction is expected to be less accretive, or more dilutive, due to amortization expense and acquisition-related charges.
With the acquisition, Boston Scientific Corporation will expand its offerings and R&D sector.
Boston Scientific has developed and provides innovative medical technologies that improve the health of patients around the world providing a broad range of solutions that address unmet patient needs and reduce the cost of health care. Its portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.
FinSMEs
18/11/2024